Botox and filler consent in Florida: more than a signed form

Informed consent for Botox or filler is a discussion about the actual proposed procedure, alternatives, and substantial risks—not just permission captured by a signature. Florida’s medical-consent statute gives qualifying written consent a rebuttable presumption of validity; it does not say that every signed template conclusively proves informed consent. Ask questions before treatment and request a copy of the product-specific plan and consent record.¹³

What Florida’s statute actually says

Section 766.103 describes a legal framework involving accepted medical practice and a reasonable person’s understanding of the procedure, medically acceptable alternatives, and substantial risks. It also addresses written consent and a valid signature.¹ These are fact-dependent legal standards, not a consumer checklist that determines liability by itself.

The practical lesson is modest but important: the content of the conversation matters. A form titled “Botox/Filler Consent” cannot tell you which product is proposed, which area will be treated, or what alternatives were discussed unless those details are actually provided.

Section 381.026 separately sets out patient rights and responsibilities within its defined scope, including information about care, the responsible provider, and refusal of treatment.² Its applicability and any particular dispute depend on the facts. This guide prepares a consultation; it does not decide whether a specific clinic has complied with Florida law.

Match the consent to the appointment in front of you

Before signing, compare the proposed service with the document. A reusable form may provide a foundation, but the record should make the individual plan understandable.

If the product, injector, treatment area, or proposed combination changes after the discussion, ask what needs to be reviewed again. A substitution can change the information needed for a meaningful decision even when the appointment price stays the same.

Alternatives include deciding not to proceed

AMA’s informed-consent guidance calls for communication about diagnosis when known, the nature and purpose of an intervention, burdens, risks, expected benefits, and alternatives, including forgoing treatment.³ In an elective aesthetic visit, that last option should be easy to discuss.

Useful questions include: What happens if I wait? Is there a less intensive approach? Does this concern require another evaluation first? What would make you recommend against treatment today? The answer need not be a comparison of every conceivable procedure. It should explain the reasonable choices relevant to the clinical assessment.

You can also separate consent from commitment to a large course of treatment. Ask what is being decided today, what remains conditional, and whether later sessions involve renewed assessment. Paying for a package does not explain the clinical basis for every future visit.

Make off-label use understandable, not mysterious

Ask whether the exact product and proposed use match current labeling. If not, ask what differs: anatomy, indication, route, population, or another element. Then ask what evidence and professional judgment support that departure.

The off-label guide explains why an off-label use differs from an unapproved product. Neither a clinic’s assurance that “everyone does it” nor the bare phrase “off-label” is a complete risk-benefit discussion.

For filler, request the patient labeling for the specific material. FDA recommends reviewing that information and discussing risks and suitability with the treating professional.⁴ If removal is part of the appeal, ask what removal actually means for that product rather than accepting a universal reversibility promise.

Keep treatment, photography, and payment permissions distinct

An intake packet may contain several documents that serve different purposes. Clinical consent addresses treatment. A financial agreement describes charges and cancellation terms. A photo authorization may concern records, teaching, or marketing. A privacy notice explains information practices.

Ask which permissions are necessary for the proposed clinical service and which are optional. If one electronic signature appears to apply to several documents, request the full packet and enough time to read it. This is a document-management question, not a claim that all combined forms are invalid.

Clarify whether a treatment photograph stays in the record or may appear in public marketing. Also distinguish consent to a clinical procedure from agreement to a discount that requires publicity. The choice is easier to evaluate when each purpose is explicit.

Use teach-back before the signature

Try summarizing the proposal in your own words: “This is the product, this is the change we are targeting, these are the main alternatives and risks, and this is who I contact afterward.” Ask the clinician to correct anything missing. A question you cannot answer is an opportunity for clarification, not a reason to rush.

Keep a copy of what you signed and the final treatment record. When comparing practices, verify the actual professional through Treomark’s practitioner records and the relevant Florida source; a polished consent form is not a license check.

The aim is a voluntary decision you can explain afterward. The signature should capture that understanding, not be the first moment you discover what the appointment entails.